As the next wave of patent cliffs loom, the pressure is on pharma to secure late-stage assets that deliver near-term value. Meanwhile, biotech leaders are navigating tighter capital markets and evolving deal structures, where milestone-heavy agreements delay returns and shift risk downstream. Join industry leaders as they share insights and advice on future-proofing partnerships in today’s complex, ever-changing landscape. Participants will learn what best-practice looks like when balancing value, risk-sharing and long-term asset potential, and how to harness complementary capabilities – scientific, operational, and commercial – to strengthen asset performance and drive better outcomes for patients.